GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (NAS:RCKT) » Definitions » Effective Interest Rate on Debt %

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Effective Interest Rate on Debt % : 7.49% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Rocket Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $1.88 Mil. Rocket Pharmaceuticals's average total debt for the quarter that ended in Dec. 2023 was $25.11 Mil. Therefore, Rocket Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 7.49%.


Rocket Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Rocket Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Effective Interest Rate on Debt % Chart

Rocket Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.40 13.83 13.97 8.40 7.83

Rocket Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.93 7.76 7.37 7.42 7.49

Competitive Comparison of Rocket Pharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Rocket Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Effective Interest Rate on Debt % falls into.



Rocket Pharmaceuticals Effective Interest Rate on Debt % Calculation

Rocket Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -1.875/( (22.866+25.042)/ 2 )
=-1  *  -1.875/23.954
=7.83 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=20.357 + 2.509
=22.866

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=22.326 + 2.716
=25.042

Rocket Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -1.88/( (25.183+25.042)/ 2 )
=-1  *  -1.88/25.1125
=7.49 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=22.331 + 2.852
=25.183

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=22.326 + 2.716
=25.042

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Rocket Pharmaceuticals  (NAS:RCKT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Rocket Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rocket Pharmaceuticals (Rocket Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Executives
John Militello officer: See Remarks C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Gotham Makker director 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Gaurav Shah director, officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Kinnari Patel officer: Chief Operating Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Mark Andrew White officer: Chief Medical Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512
Jonathan David Schwartz officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fady Ibraham Malik director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Martin Wilson officer: General Counsel C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Carlos Garcia-parada officer: Chief Financial Officer C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118
Elisabeth Bjork director C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116
Kamran Alam officer: SVP - Finance & PFO 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
David P Southwell director, officer: See Remarks C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Naveen Yalamanchi director 412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019
Brian Batchelder officer: See Remarks 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016

Rocket Pharmaceuticals (Rocket Pharmaceuticals) Headlines

From GuruFocus